Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust Sells 9,127 Shares of Thermo Fisher Scientific Inc. $TMO

Posted by Stanley Muller on Oct 20th, 2026

Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 34.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 17,118 shares of the medical research company’s stock after selling 9,127 shares during the quarter. Thermo Fisher Scientific makes up approximately 2.8% of Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust’s holdings, making the stock its 11th biggest holding. Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust’s holdings in Thermo Fisher Scientific were worth $11,556,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in TMO. Jeppson Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the 3rd quarter worth about $213,000. James Hambro & Partners LLP raised its holdings in Thermo Fisher Scientific by 0.8% during the third quarter. James Hambro & Partners LLP now owns 231,390 shares of the medical research company’s stock worth $156,260,000 after purchasing an additional 1,919 shares in the last quarter. James T. Borello RIA bought a new position in Thermo Fisher Scientific during the third quarter valued at about $57,000. V Square Quantitative Management LLC boosted its position in shares of Thermo Fisher Scientific by 2.2% during the 3rd quarter. V Square Quantitative Management LLC now owns 2,451 shares of the medical research company’s stock valued at $1,655,000 after purchasing an additional 53 shares in the last quarter. Finally, YANKCOM Partnership grew its position in Thermo Fisher Scientific by 4.7% in the third quarter. YANKCOM Partnership now owns 1,405 shares of the medical research company’s stock worth $948,000 after buying an additional 63 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $679.48 on Tuesday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The firm’s 50-day simple moving average is $638.93 and its 200-day simple moving average is $549.90. The firm has a market cap of $251.24 billion, a P/E ratio of 28.95, a price-to-earnings-growth ratio of 2.89 and a beta of 0.87. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $704.00.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc Casper sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at $77,982,284.75. This represents a 7.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph Holmes sold 420 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the transaction, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 73,768 shares of company stock worth $44,122,820 over the last quarter. Corporate insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TMO. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $720.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, September 25th. Royal Bank Of Canada set a $740.00 price objective on Thermo Fisher Scientific in a report on Thursday. Piper Sandler assumed coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, September 9th. They set an “overweight” rating on the stock. CLSA initiated coverage on Thermo Fisher Scientific in a report on Thursday, September 3rd. They set an “outperform” rating and a C$748.00 price objective on the stock. Finally, Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $654.05.

Read Our Latest Stock Report on TMO

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.